Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.

Author: BrennerDarren M, SayukGregory S

Paper Details 
Original Abstract of the Article :
Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by abdominal pain and alterations in stool form and/or frequency, leading to reduced quality of life. Pharmacologic agents currently approved by the US Food and Drug Administration for treatment of IBS with diarrhea (IBS-D) ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s12325-019-01116-z

データ提供:米国国立医学図書館(NLM)

Pharmacologic Therapies for Irritable Bowel Syndrome with Diarrhea (IBS-D)

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that can significantly impact a person's quality of life. This research focuses on the pharmacologic therapies currently approved by the US Food and Drug Administration (FDA) for the treatment of IBS with diarrhea (IBS-D) in adults.

The authors provide an overview of three FDA-approved medications for IBS-D: rifaximin (a nonsystemic antibiotic), eluxadoline (a mixed µ- and κ-opioid receptor agonist/δ-opioid antagonist), and alosetron (a selective serotonin 5-HT3 antagonist). They delve into the mechanisms of action, efficacy, and safety of each medication, highlighting their role in managing the symptoms of IBS-D.

The study concludes that rifaximin, eluxadoline, and alosetron have demonstrated efficacy and safety in treating IBS-D. These medications offer valuable treatment options for managing the symptoms of this condition, potentially improving the quality of life for individuals with IBS-D.

Medication Options for IBS-D

The study identifies three FDA-approved medications that have shown efficacy and safety in treating IBS-D: rifaximin, eluxadoline, and alosetron. These medications provide valuable options for managing the symptoms of IBS-D, potentially improving the quality of life for patients.

Managing IBS-D: A Collaborative Approach

If you are struggling with IBS-D, it's important to consult with your healthcare provider to discuss the most appropriate treatment options. This research highlights the availability of FDA-approved medications that can effectively manage IBS-D symptoms. Remember that the best approach is to work in collaboration with your doctor to find a treatment plan that is right for you.

Dr.Camel's Conclusion

Imagine navigating a scorching desert, where the heat and discomfort are relentless. IBS-D can feel like that, with unpredictable symptoms that disrupt your daily life. This research sheds light on the medications available to help manage this condition. It's a reminder that even in the most challenging landscapes, there can be solutions to alleviate discomfort and improve your journey. Remember, seeking professional guidance and working in partnership with your doctor is key to finding relief and managing IBS-D effectively.

Date :
  1. Date Completed 2020-10-07
  2. Date Revised 2020-10-07
Further Info :

Pubmed ID

31707713

DOI: Digital Object Identifier

10.1007/s12325-019-01116-z

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.